ClinicalTrials.gg
Not yet recruitingNCT07678151Updated Jul 1, 2026

Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial

An interventional study of Empagliflozin and Finerenone and Placebo for Empagliflozin and Finerenone in Hypertension (HTN), sponsored by Heart Health Research Center. Not yet recruiting at 2 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Heart Health Research Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
149th of 308
260 · median 253
Started
2026
with 37 others
No phase
146 of 410
56 open now
Primary completion
2027-04
later than 95 of 147 live
Registered
388th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 149th largest by planned enrollment of the 308 interventional ones that give a count, is one of 38 that started in 2026, is one of 146 with no phase, reaches primary completion later than 95 of the 147 other live ones, and was the 388th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg/day) with finerenone (10 mg/day, up-titrated to 20 mg after 4 weeks) can significantly lower office systolic blood pressure in adults with obesity and stage 1 hypertension (systolic BP 140-160 mmHg) who are on up to two stable antihypertensives. The study will enroll 260 participants from community settings. Beyond blood pressure, the trial will also assess effects on diastolic pressure, cumulative BP exposure, urinary albumin-to-creatinine ratio, inflammation (hs-CRP), fasting glucose, body weight, and quality of life. Safety monitoring focuses on hyperkalemia, acute kidney injury, hypotension, and hypoglycemia. If positive, this research may offer a new, mechanism-based therapeutic strategy for the growing population with cardiometabolic risk, potentially providing better cardiovascular and kidney protection than conventional approaches.

03

Conditions studied

  • Hypertension (HTN)

Keywords

  • Sodium-Glucose Transporter 2 Inhibitors
  • Mineralocorticoid Receptor Antagonists
  • Blood Pressure
  • Obesity
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 40 years.

(BMI) ≥ 28 kg/m² or abdominal obesity, defined as meeting any of the following:

Waist circumference ≥ 90 cm (male) or ≥ 85 cm (female); Waist-to-hip ratio ≥ 0.9 (male) or ≥ 0.85 (female); Waist-to-height ratio ≥ 0.5. Unattended office systolic blood pressure (SBP) ≥ 140 mmHg and \< 160 mmHg during the screening period (within 1 week before randomization).

Currently taking no more than 2 antihypertensive agents (fixed-dose combinations are counted by the number of active ingredients).

No changes in the type or dose of antihypertensive medications within 4 weeks before the screening visit.

Provide written .

Exclusion criteria

Exclusion Criteria:

Diastolic blood pressure ≥ 100 mmHg. Diagnosed diabetes mellitus or fasting plasma glucose ≥ 7.0 mmol/L. History of heart failure (any ) or left ventricular ejection fraction \< 50%.

Acute coronary syndrome, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) within 90 days.

Stroke or (TIA) within 90 days. Known secondary hypertension (e.g., bilateral renal artery stenosis >75%, aldosteronism, pheochromocytoma), except documented sleep apnea.

Severe hepatic dysfunction (/ALT > 3× , or class C).

Acute kidney injury within 6 months before screening, or \< 60 mL/min/1.73 m², or kidney transplant (or planned).

Primary adrenal insufficiency (Addison's disease). to any component of the study drugs (e.g., urinary tract infection within 90 days, serum potassium > 5.0 mmol/L, drug allergy).

Major surgery under general anesthesia within 90 days before screening, or elective surgery planned within 90 days after screening.

Gastrointestinal surgery or disease that, in the investigator's judgment, may affect absorption of the study drug.

Pregnancy, lactation, or planned pregnancy (for both male and female participants) during the study period.

Active . \< 3 months. Use of strong inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampicin, carbamazepine, phenytoin) that cannot be discontinued within 7 days before Day 1.

Use of mineralocorticoid receptor antagonists (e.g., finerenone, eplerenone, spironolactone), renin inhibitors, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), or SGLT-1/2 inhibitors (e.g., canagliflozin) within 8 weeks before screening or during the intervention period.

Use of potassium supplements, potassium-sparing diuretics (e.g., amiloride, triamterene), or potassium-binding agents within 8 weeks before screening or during the intervention period.

Participation in a clinical trial of empagliflozin or finerenone within 1 month before screening.

Current use of weight-loss medications (e.g., GLP-1 receptor agonists, GIP/GLP-1 dual agonists, GLP-1/GCGR dual agonists) or prior/planned bariatric surgery.

Known or suspected orthostatic hypotension or autonomic dysfunction. Any condition that, in the investigator's opinion, makes the participant unsuitable for the study.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Participants receive empagliflozin 10 mg oral tablet once daily plus finerenone 10 mg oral tablet once daily for 12 weeks. At Week 4 (visit 3, ±4 days), the finerenone dose may be up-titrated to 20 mg once daily if the following criteria are met: serum potassium ≤4.8 mmol/L and estimated glomerular filtration rate (eGFR) decline \<30% from the previous visit's value.

    Drug: Empagliflozin and Finerenone

  • Placebo comparator
    Control group

    Participants receive matching placebo for empagliflozin 10 mg oral tablet once daily plus matching placebo for finerenone 10 mg oral tablet once daily for 12 weeks. To maintain blinding, a sham up-titration of the finerenone placebo is performed at Week 4 (visit 3, ±4 days) using the same criteria simulation.

    Drug: Placebo for Empagliflozin and Finerenone

Interventions

  • DrugEmpagliflozin and Finerenone

    Drug pages: EmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FinerenoneStudies of FinerenoneFinerenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is a fixed-dose combination of two oral medications-empagliflozin (a sodium-glucose cotransporter 2 inhibitor) and finerenone (a nonsteroidal mineralocorticoid receptor antagonist)-administered simultaneously as separate tablets once daily for 12 weeks. The intervention consists of empagliflozin 10 mg once daily plus finerenone 10 mg once daily, taken orally in the morning with or without food.

  • DrugPlacebo for Empagliflozin and Finerenone

    Participants receive two matching placebo tablets orally once daily in the morning, with or without food, for 12 weeks: one placebo matching empagliflozin 10 mg and one placebo matching finerenone 10 mg. Both placebos are identical in appearance, size, shape, color, and taste to the corresponding active study drugs to ensure complete double-blinding.

06

What researchers measure

Primary outcomes

  1. Change in Unattended Office Systolic Blood Pressure From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5, end-of-treatment visit)

Secondary outcomes

  1. Change in Unattended Office Diastolic Blood Pressure From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5)

  2. Change in Cumulative Blood Pressure Exposure From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5)

  3. Change in Log-Transformed Urinary Albumin-to-Creatinine Ratio From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5)

  4. Change in High-Sensitivity C-Reactive Protein From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5)

  5. Change in Fasting Plasma Glucose From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5)

  6. Change in Body Weight From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5)

  7. Change in EQ-5D Quality of Life Score From Baseline to Week 12

    Time frame: Baseline (Day 1) to Week 12 (visit 5)

  8. Proportion of Participants Achieving Strict Blood Pressure Control at Week 12

    Time frame: Week 12 (visit 5)

  9. Proportion of Participants With SBP >160 mmHg or Initiation of Additional Antihypertensive Therapy Within 12 Weeks

    Time frame: Baseline (Day 1) through Week 12 (visit 5)

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Apr 2027, 9 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 9 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartEst.
Jul 13, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07678151
Lead sponsor
Heart Health Research Center
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Jul 13, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Xin Du, Professor
Contact
duxinheart@sina.com
+8613370103558
Rong Han
Contact
hanrong@hhresearch.cn
+86 13910669903
Xin Du
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Finerenone

Start the discussion